Global Wilson's Disease Drugs Market 2019-2023: Pharmaceutical Companies are Engaging in Strategic Alliances for the Development of Medications

Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Wilson's Disease Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The increase in strategic alliances to help market grow. Pharmaceutical companies are engaging in strategic alliances for the development of medications for the treatment of Wilson's disease. These alliances enhance the R&D activities for new drugs for the treatment of Wilson's disease. The analysts have predicted that the Wilson's disease drugs market will register a CAGR of almost 6% by 2023.

Market Overview

Increasing introduction of patient assistance programs

Patient assistance programs have been introduced to help patients who lack health insurance or prescription drug coverage to obtain the medications they need.

High cost of treatment

Despite the benefits of chelators, the price of these medicines poses a challenge to the market growth. The high cost of chelators will result in low patient adherence to chelator therapy. This, in turn, will hinder the growth of the global Wilson's disease drugs market.

For the detailed list of factors that will drive and challenge the growth of the Wilson's disease drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bausch Health Companies and Mylan the competitive environment is quite intense. Factors such as the rising increase in strategic alliances and increasing introduction of patient assistance programs, will provide considerable growth opportunities to Wilson's disease drugs manufactures. Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati are some of the major companies covered in this report.

With the presence of a considerable number of companies, this market appears to be fragmented. The strategic alliances enhance the R&D activities for new drugs for the treatment of Wilson's disease. Such alliances help companies develop new drugs for the treatment of Wilson's disease. It also helps in the faster development of therapeutic products.'

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Chelators - Market size and forecast 2018-2023
• Minerals - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bausch Health Companies
• Mylan
• Recordati
• Teva Pharmaceutical Industries
• TSUMURA

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/8x2dqr/global_wilsons?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Central Nervous System Drugs